Aclaris Therapeutics (NASDAQ:ACRS) Stock Rating Cut to Sell at Wall Street Zen

Wall Street Zen lowered shares of Aclaris Therapeutics (NASDAQ:ACRS – Free Report) from a hold rating to a sell rating in a report released on Saturday morning,Wall Street Zen reports.

Other analysts have also recently issued reports about the company. Canaccord Genuity Group dropped their price objective on Aclaris Therapeutics from $13.00 to $12.00 and set a “buy” rating for the company in a report on Tuesday, November 17th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Aclaris Therapeutics in a research report on Monday, September 21st. HC Wainwright reiterated a “buy” rating and set a $16.00 price target on shares of Aclaris Therapeutics in a research report on Wednesday, October 28th. Craig Hallum set a $9.00 price target on shares of Aclaris Therapeutics in a research note on Wednesday, October 28th. Finally, Wedbush lowered shares of Aclaris Therapeutics from an “outperform” rating to a “neutral” rating and cut their price objective for the company from $8.00 to $3.00 in a report on Tuesday, November 17th. Three analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Buy” and a consensus price target of $10.67.

View Our Latest Report on Aclaris Therapeutics

Aclaris Therapeutics Stock Performance

NASDAQ ACRS opened at $3.44 on Friday. The stock has a fifty day moving average of $4.21 and a 200-day moving average of $4.53. The stock has a market capitalization of $545.62 million, a P/E ratio of -5.93 and a beta of 0.96. Aclaris Therapeutics has a 52 week low of $2.34 and a 52 week high of $6.60.

Aclaris Therapeutics (NASDAQ:ACRS – Get Free Report) last issued its quarterly earnings results on Thursday, November 5th. The biotechnology company reported ($0.12) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.16) by $0.04. The business had revenue of $1.48 million for the quarter, compared to analyst estimates of $1.27 million. Aclaris Therapeutics had a negative return on equity of 59.19% and a negative net margin of 1,244.09%. Equities research analysts forecast that Aclaris Therapeutics will post -0.56 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Aclaris Therapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Sei Investments Co. bought a new stake in shares of Aclaris Therapeutics in the 1st quarter valued at about $814,000. Bank of New York Mellon Corp bought a new position in Aclaris Therapeutics during the 2nd quarter worth approximately $1,495,000. Dimensional Fund Advisors LP raised its holdings in Aclaris Therapeutics by 88.8% in the first quarter. Dimensional Fund Advisors LP now owns 511,461 shares of the biotechnology company’s stock worth $1,914,000 after purchasing an additional 240,611 shares during the period. Palo Alto Investors LP bought a new position in shares of Aclaris Therapeutics during the second quarter worth $8,535,045. Finally, Deutsche Bank AG acquired a new position in shares of Aclaris Therapeutics in the 2nd quarter valued at $5,507,000. Institutional investors own 98.34% of the company’s stock.

About Aclaris Therapeutics

(Get Free Report)

Aclaris Therapeutics is a biopharmaceutical company focused on discovering and developing treatments for immuno-inflammatory diseases. Its research programs include small-molecule therapies designed to target pathways involved in inflammation and immune responses. The company’s development portfolio has included candidates for dermatologic and other inflammatory conditions. Aclaris previously developed ESKATA, a topical treatment for raised seborrheic keratoses that received U.S. regulatory approval in 2017.

Recommended Stories

Analyst Recommendations for Aclaris Therapeutics (NASDAQ:ACRS)

Receive News & Ratings for Aclaris Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aclaris Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.